Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

674 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
Underwood E, Dunkle LM, Madhi SA, Gay CL, Heath PT, Kotloff KL, Smith K, Chau G, Galbiati S, McGarry A, Woo W, Cho I, Alves K, Áñez G, Bennett C, Shinde V, Fries L, Mallory RM, Glenn GM, Toback S. Underwood E, et al. Among authors: madhi sa. Expert Rev Vaccines. 2023 Jan-Dec;22(1):501-517. doi: 10.1080/14760584.2023.2218913. Expert Rev Vaccines. 2023. PMID: 37246757 Free article. Review.
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.
Bhiman JN, Richardson SI, Lambson BE, Kgagudi P, Mzindle N, Kaldine H, Crowther C, Gray G, Bekker LG; Novavax trial clinical lead author group; Shinde V, Bennett C, Glenn GM, Madhi SA, Moore PL. Bhiman JN, et al. Among authors: madhi sa. Sci Rep. 2023 Jan 21;13(1):1222. doi: 10.1038/s41598-023-27698-x. Sci Rep. 2023. PMID: 36681693 Free PMC article.
Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial.
Bennett C, Hoosain Z, Koen A, Lalloo U, Louw C, Maluleke V, Patel F, Benade G, Venter EL, Galbiati S, Shinde V, Madhi SA; Study 2019nCoV-505 Investigators Group. Bennett C, et al. Among authors: madhi sa. J Infect. 2024 Dec;89(6):106285. doi: 10.1016/j.jinf.2024.106285. Epub 2024 Sep 27. J Infect. 2024. PMID: 39343247 Free article. Clinical Trial.
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
Bebia Z, Reyes O, Jeanfreau R, Kantele A, De Leon RG, Sánchez MG, Banooni P, Gardener GJ, Rasero JLB, Pardilla MBE, Langley JM, Di Leo CM, Botelho-Nevers E, Buttery J, Laurichesse H, Madhi SA, García AM, Stanley T, Barjat T, Griffith R, Castrejón-Alba MM, de Heusch M, Dieussaert I, Hercor M, Lese P, Qian H, Tullio AN, Henry O. Bebia Z, et al. Among authors: madhi sa. J Infect Dis. 2023 Aug 11;228(3):299-310. doi: 10.1093/infdis/jiad024. J Infect Dis. 2023. PMID: 36722147 Free PMC article. Clinical Trial.
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.
Motsoeneng BM, Manamela NP, Kaldine H, Kgagudi P, Hermanus T, Ayres F, Makhado Z, Moyo-Gwete T, van der Mescht MA, Abdullah F, Boswell MT, Ueckermann V, Rossouw TM, Madhi SA, Moore PL, Richardson SI. Motsoeneng BM, et al. Among authors: madhi sa. Front Immunol. 2023 Aug 3;14:1231276. doi: 10.3389/fimmu.2023.1231276. eCollection 2023. Front Immunol. 2023. PMID: 37600825 Free PMC article.
Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study.
Reiter L, Greffrath J, Zidel B, Ostrowski M, Gommerman J, Madhi SA, Tran R, Martin-Orozco N, Panicker RKG, Cooper C, Pastrak A. Reiter L, et al. Among authors: madhi sa. Sci Rep. 2024 Mar 4;14(1):5365. doi: 10.1038/s41598-024-55320-1. Sci Rep. 2024. PMID: 38438427 Free PMC article. Clinical Trial.
Neurological Symptoms and Cause of Death Among Young Children in Low- and Middle-Income Countries.
Ajanovic S, Madewell ZJ, El Arifeen S, Gurley ES, Hossain MZ, Islam KM, Rahman A, Assefa N, Madrid L, Abdulahi M, Igunza KA, Murila F, Revathi G, Christopher M, Sow SO, Kotloff KL, Tapia MD, Traor CB, Mandomando I, Xerinda E, Varo R, Kincardett M, Ogbuanu IU, Nwajiobi-Princewill P, Swarray-Deen A, Luke R, Madhi SA, Mahtab S, Dangor Z, du Toit J, Akelo V, Mutevedzi P, Tippett Barr BA, Blau DM, Whitney CG, Bassat Q; Child Health and Mortality Prevention Surveillance (CHAMPS) Consortium. Ajanovic S, et al. Among authors: madhi sa. JAMA Netw Open. 2024 Sep 3;7(9):e2431512. doi: 10.1001/jamanetworkopen.2024.31512. JAMA Netw Open. 2024. PMID: 39226053 Free PMC article.
Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa.
Sokhela S, Bosch B, Hill A, Simmons B, Woods J, Johnstone H, Madhi S, Qavi A, Ellis L, Akpomiemie G, Bhaskar E, Levi J, Falconer J, Mirchandani M, Perez Casas C, Moller K, Pilkington V, Pepperrell T, Venter WDF. Sokhela S, et al. Open Forum Infect Dis. 2022 Dec 16;9(12):ofac587. doi: 10.1093/ofid/ofac587. eCollection 2022 Dec. Open Forum Infect Dis. 2022. PMID: 36540387 Free PMC article.
674 results